ProfileGDS5678 / 1433483_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 37% 36% 37% 36% 40% 37% 36% 36% 36% 36% 36% 35% 36% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8782837
GSM967853U87-EV human glioblastoma xenograft - Control 22.8280736
GSM967854U87-EV human glioblastoma xenograft - Control 32.8372637
GSM967855U87-EV human glioblastoma xenograft - Control 42.7713136
GSM967856U87-EV human glioblastoma xenograft - Control 52.8720240
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9352237
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8718936
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8073936
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7941236
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7993336
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8165436
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7670835
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8293736
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8296537